Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©

Jansen C1*, Wagner RM1*, Praktiknjo M2, Chang J1, Böhling N1, Kaczmarek D1, Lehmann J1, Strassburg CP1 and Trebicka J1,2,3

1Department of Internal Medicine I, University of Bonn, Germany
2Medical Department B, University Clinic Münster, Germany
3European Foundation for Study of Chronic Liver Failure, Spain

^*Correspondance to: Christian Jansen 

 PDF  Full Text DOI: 10.25107/2474-1647.3596

Abstract

Background: Ascites is the common cause of decompensation in patients with cirrhosis. It has been ascertained that 5% to 10% of patients with end stage liver disease showed in case of compensation the develop of ascites every year. The alfapump© reduces the need for large volume paracentesis and can improve life quality. The aim of our study was to assess the role of the use of Non-Selective Beta-Blocker (NSBB) characteristics and outcomes of patients with cirrhosis receiving alfapump© and to find predictors of a longer life in a palliative concept. Methods: Seventeen (13 males) patients with liver cirrhosis receiving an alfapump© were included in this case-series. Clinical parameters were assessed before the insertion of the alfapump© and during follow-up. As part of the follow-up, all patients received the standard of care as recommended by European Association for the Study of the Liver and DGVS. Results: Could generally be identified as the cause of death. If the patients were stratified according to the use of a non-selective beta-blocker, we can see that the group taking non-selective beta blocker had a longer survival. These data to verify previous finding that NSBB in this very high-risk patient may delay infections and improve outcome. Conclusion: This study suggests a protective effect of NSBB in patients after implantation of an alfapump©. Although confirmation is needed, this may help management of patients receiving the device.

Keywords

Cite the article

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, et al. Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©. Clin Surg. 2022; 7: 3596..